共 112 条
[1]
Portman DJ(2014)Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society Maturitas. 79 349-354
[2]
Gass MLS(2014)Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause Climact J Int Menopause Soc 17 3-9
[3]
Nappi RE(2014)Management of vaginal atrophy: implications from the REVIVE survey Clin Med Insights Reprod Health 8 23-30
[4]
Palacios S(2013)Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society Menopause 20 888-902
[5]
Wysocki S(2015)Update on management of genitourinary syndrome of menopause: a practical guide Maturitas 82 308-313
[6]
Kingsberg S(2013)Spanish Menopause Society position statement: use of tibolone in postmenopausal women Menopause 20 754-760
[7]
Krychman M(2016)Local oestrogen for vaginal atrophy in postmenopausal women Cochrane Database Syst Rev 8 CD001500-727
[8]
Palacios S(1998)Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee Obstet Gynecol 92 722-424
[9]
Castelo-Branco C(2017)The Women’s EMPOWER survey: identifying women’s perceptions on vulvar and vaginal atrophy and its treatment J Sex Med 14 413-159
[10]
Currie H(2017)Light and energy based therapeutics for genitourinary syndrome of menopause: consensus and controversies Lasers Surg Med 49 137-518